← Leaderboards
David M Koelle
Fred Hutchinson Cancer Research Center
$18,912,642
Attributed
$19,130,542
Total exposure
16
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2005–23$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$19,130,542 · 16
By mechanism
R01$8,089,035 · 4
P01$5,288,465 · 4
U19$3,345,713 · 2
R21$2,107,713 · 5
R41$299,616 · 1
Top collaborators
- Ruth Harbecke2 shared
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocytePersonsCellsAntigensCd4 Positive T LymphocytesInfectionSiteBloodSkinImmuneT Cell ResponseSpecificityImmune ResponseResponseVaccinesVirusPathogenMemoryVaccinationSimplexvirusTissuesBaseCd8b1 GeneHoming
Grant awards (55)
Specific T and B cell responses to candidate Treponema pallidum outer membrane protein vaccine antigens$638,650
U19 · FY2023 · AI · contact PI
Cutaneous pathogen-specific tissue resident memory T cells in human aging$558,723
R01 · FY2023 · AG · contact PI
Project 3: Adaptive immunity to MCPyV in Merkel cell carcinoma$423,325
P01 · FY2023 · CA · contact PI
Specific T and B cell responses to candidate Treponema pallidum outer membrane protein vaccine antigens$670,512
U19 · FY2022 · AI · contact PI
Cutaneous pathogen-specific tissue resident memory T cells in human aging$558,757
R01 · FY2022 · AG · contact PI
Project 3: Adaptive immunity to MCPyV in Merkel cell carcinoma$454,020
P01 · FY2022 · CA · contact PI
C19 SARS-CoV-2-specific T cells in the infected nasel epithelium$220,624
R21 · FY2022 · AI · contact PI
Specific T and B cell responses to candidate Treponema pallidum outer membrane protein vaccine antigens$756,388
U19 · FY2021 · AI · contact PI
Cutaneous pathogen-specific tissue resident memory T cells in human aging$561,763
R01 · FY2021 · AG · contact PI
Project 3: Adaptive immunity to MCPyV in Merkel cell carcinoma$500,195
P01 · FY2021 · CA · contact PI
C19 SARS-CoV-2-specific T cells in the infected nasel epithelium$264,749
R21 · FY2021 · AI · contact PI
DOES REDUCED HSV PREVALENCE RESULT IN INCREASED ZOSTER INCIDENCE IN THE US?$192,194
R21 · FY2021 · AI · contact PI
Specific T and B cell responses to candidate Treponema pallidum outer membrane protein vaccine antigens$693,924
U19 · FY2020 · AI · contact PI
Cutaneous pathogen-specific tissue resident memory T cells in human aging$563,301
R01 · FY2020 · AG · contact PI
Project 3: Adaptive immunity to MCPyV in Merkel cell carcinoma$543,162
P01 · FY2020 · CA · contact PI
Cutaneous Pathogen-Specific Tissue Resident Memory T Cells in Human Aging$396,241
R01 · FY2020 · AG · contact PI
DOES REDUCED HSV PREVALENCE RESULT IN INCREASED ZOSTER INCIDENCE IN THE US?$243,606
R21 · FY2020 · AI · contact PI
Cutaneous pathogen-specific tissue resident memory T cells in human aging$172,599
R01 · FY2020 · AG · contact PI
Specific T and B cell responses to candidate Treponema pallidum outer membrane protein vaccine antigens$586,239
U19 · FY2019 · AI · contact PI
Cutaneous pathogen-specific tissue resident memory T cells in human aging$539,337
R01 · FY2019 · AG · contact PI
Project 3: Adaptive immunity to MCPyV in Merkel cell carcinoma$461,978
P01 · FY2019 · CA · contact PI
Cutaneous pathogen-specific tissue resident memory T cells in human aging$173,983
R01 · FY2019 · AG · contact PI
Integrated Human Immune Responses to HSV$290,194
P01 · FY2017 · AI · contact PI
Genomic systems approach to measure HSV-1-specific T-cell dominance in humans$435,000
R01 · FY2016 · AI · contact PI
Integrated Human Immune Responses to HSV$279,480
P01 · FY2016 · AI · contact PI
Genomic systems approach to measure HSV-1-specific T-cell dominance in humans$435,000
R01 · FY2015 · AI · contact PI
Integrated Human Immune Responses to HSV$271,542
P01 · FY2015 · AI · contact PI
Genomic systems approach to measure HSV-1-specific T-cell dominance in humans$435,000
R01 · FY2014 · AI · contact PI
Integrated Human Immune Responses to HSV$337,055
P01 · FY2014 · AI · contact PI
Genomic systems approach to measure HSV-1-specific T-cell dominance in humans$291,184
R01 · FY2013 · AI · contact PI
Integrated Human Immune Responses to HSV$278,008
P01 · FY2013 · AI · contact PI
Genomic systems approach to measure HSV-1-specific T-cell dominance in humans$304,726
R01 · FY2012 · AI · contact PI
Local Determinants of HSV-2 Shedding in Humans$230,702
P01 · FY2012 · AI · contact PI
Local Determinants of HSV-2 Shedding in Humans$294,566
P01 · FY2011 · AI · contact PI
Local Determinants of HSV-2 Shedding in Humans$173,051
P01 · FY2010 · AI · contact PI
HSV-1-specific T-cell responses in human sensory ganglia$150,630
R21 · FY2010 · AI · contact PI
Vaccinia: T-cell immunity and homing to skin$334,345
R01 · FY2009 · AI · contact PI
HSV-1-specific T-cell responses in human sensory ganglia$182,130
R21 · FY2009 · AI · contact PI
Local Determinants of HSV-2 Shedding in Humans$175,572
P01 · FY2009 · AI · contact PI
Vaccinia: T-cell immunity and homing to skin$334,346
R01 · FY2008 · AI · contact PI
Local Determinants of HSV-2 Shedding in Humans$180,963
P01 · FY2008 · AI · contact PI
Vaccinia: T-cell immunity and homing to skin$340,822
R01 · FY2007 · AI · contact PI
Immune Correlates of HSV-2 Disease Severity$251,553
R01 · FY2007 · AI · contact PI
Vaccinia: T-cell immunity and homing to skin$349,969
R01 · FY2006 · AI · contact PI
Immune Correlates of HSV-2 Disease Severity$259,066
R01 · FY2006 · AI · contact PI
Intradermal vaccinia:T-cell specificity and skin homing$303,200
R21 · FY2005 · AI
HSV Immunotherapeutic Vaccine$299,616
R41 · FY2005 · AI
Immune Correlates of HSV-2 Disease Severity$265,300
R01 · FY2005 · AI
Intradermal vaccinia:T-cell specificity and skin homing$290,300
R21 · FY2004 · AI
Immune Correlates of HSV-2 Disease Severity$265,300
R01 · FY2004 · AI
Immune Correlates of HSV-2 Disease Severity$262,720
R01 · FY2003 · AI
MUCOSAL T CELL RESPONSES TO HSV INFECTIONS$228,401
P01 · FY2002 · AI
Immune Correlates of HSV-2 Disease Severity$260,280
R21 · FY2001 · AI
MUCOSAL T CELL RESPONSES TO HSV INFECTIONS$0
P01 · FY2001 · AI
MUCOSAL T CELL RESPONSES TO HSV INFECTIONS$166,251
P01 · FY2000 · AI